Abstract
The biotransformation of venlafaxine (VF) into its two major metabolites, O-desmethylvenlafaxine (ODV) and N-desmethylvenlafaxine (NDV) was studied in vitro with human liver microsomes and with microsomes containing individual human cytochromes from cDNA-transfected human lymphoblastoid cells. VF was coincubated with selective cytochrome P450 (CYP) inhibitors and several selective serotonin reuptake inhibitors (SSRIs) to assess their inhibitory effect on VF metabolism. Formation rates for ODV incubated with human microsomes were consistent with Michaelis-Menten kinetics for a single-enzyme mediated reaction with substrate inhibition. Mean parameters determined by non-linear regression were: Vmax = 0.36 nmol/min/mg protein, Km = 41 μM, and Ks 22901 μM (Ks represents a constant which reflects the degree of substrate inhibition). Quinidine (QUI) was a potent inhibitor of ODV formation with a Ki of 0.04 μM, and paroxetine (PX) was the most potent SSRI at inhibiting ODV formation with a mean Ki value of 0.17 μM. Studies using expressed cytochromes showed that ODV was formed by CYP2C9, −2C19, and −2D6. CYP2D6 was dominant with the lowest Km, 23.2 μM, and highest intrinsic clearance (Vmax/Km ratio). No unique model was applicable to the formation of NDV for all four livers tested. Parameters determined by applying a single-enzyme model were Vmax = 2.14 nmol/min/mg protein, and Km = 2504 μM. Ketoconazole was a potent inhibitor of NDV production, although its inhibitory activity was not as great as observed with pure 3A substrates. NDV formation was also reduced by 42% by a polyclonal rabbit antibody against rat liver CYP3A1. Studies using expressed cytochromes showed that NDV was formed by CYP2C9, −2C19, and −3A4. The highest intrinsic clearance was attributable to CYP2C19 and the lowest to CYP3A4. However the high in vivo abundance of 3A isoforms will magnify the importance of this cytochrome. Fluvoxamine (FX), at a concentration of 20 μM, decreased NDV production by 46% consistent with the capacity of FX to inhibit CYP3A, 2C9, and 2C19. These results are consistent with previous studies that show CYP2D6 and −3A4 play important roles in the formation of ODV and NDV, respectively. In addition we have shown that several other CYPs have important roles in the biotransformation of VF.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Ball SE, Ahern D, Scatina J, Kao J . (1997): Venlafaxine: In vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9, and CYP1A2. Br J Clin Pharmacol 43: 619–626
Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, Brosen K . (1998): The oxidative metabolism of metoprolol in human liver microsomes: Inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol 54: 261–264
Crespi CL . (1995): Xenobiotic—metabolizing human cells as tools for pharmacological and toxicological research. Advances Drug Res 26: 179–235.
Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE . (1992): The effect of selective serotonin reuptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34: 262–265
Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamond BI, Fischer DE, Hearst E . (1994): A comparison of venlafaxine, trazadone, and placebo in major depression. J Clin Psychopharm 14: 99–106
Findling RL, Schwartz MA, Flannery DJ, Manos MJ . (1996): Venlafaxine in adults with attention-deficit/hyperactivity disorder: an open clinical trial. J Clin Psych 57: 184–189
Geracioti TD . (1995): Venlafaxine treatment of panic disorder: A case series. J Clin Psych 56: 408–410
Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T, Kuroiwa Y . (1997): Identification of cytochrome P450 isoforms involved in citalopram N-demthylation by human liver microsome. JPET 280: 927–933
Motulsky HJ, Ransnas LA . (1987): Fitting curves to data using nonlinear regression: A practical and nonmathematical review. FASEB 1: 365–374
Muth EA, Haskins JT, Moyer JA, Husbands GEM, Nielsen ST, Sig EB . (1986): Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, an ethyl cyclohexanol derivative. Biochem Pharmacol 5: 4493–4497
Muth EA, Moyer JA, Haskins JT . (1991): Biochemical, neurophysiological, and behavioral effects of WY-45, 233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res 23: 191–199
Newton DJ, Wang RW, Lu AYH . (1995): Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23: 154–158
Nielsen KK, Flinois JP, Beaune P, Brosen K . (1996): The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 77: 1659–1664
Norby J, Rubenstein S, Tuerke T, Farmer S, Forood R, Bennington J . (1991): Sigma Plot, v. 2.00. Jandel Corporation.
Otton SV, Ball SE, Cheung SW, Inaba T, Rudolph RL, Sellers EM . (1996): Venlafaxine oxidation in vitro is catalyzed by CYP2D6. Br J Clin Pharmacol 41: 149–156
Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM . (1993): Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 53: 401–409
Ring BJ, Binkley SN, Roskos L, Wrighton SA . (1995): Effect of fluoxetine, norfluoxetine, sertraline, and desmethylsertraline on human CYP3A catalyzed 1′-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 275: 1131–1135
Schmider J, Greenblatt DJ, Harmatz JS, Shader RI . (1996): Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation. Br J Clin Pharmacol 41: 593–604
Schmider J, Greenblatt DJ, von Moltke LL, Harmatz JS, Shader RI . (1995): N-demethylation of amitriptyline in vitro: Role of cytochrome P-450 3A (CYP3A) isoforms and effect of metabolic inhibitors. J Pharmacol Exp Ther 275: 592–597
Schweizer E, Feighner J, Mandos LA, Rickels K . (1994): Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psych 55: 104–108
Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP . (1994): Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and 30 Caucasians. JPET 270: 414–423
Skjelbo E, Brøsen K . (1992): Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34: 256–261
Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Schmider J, Harmatz JS, Shader RI . (1998a): Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: Dominance of CYP2C19 and 3A4. J Clin Pharmacol 38: 112–121
Venkatakrishnan K, von Moltke LL, Greenblatt DJ . (1998b): Relative quantities of catalytically active CYP2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. J Pharm Sci 87: 845–853
von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, Duan SX, Harmatz JS, Shader RI . (1994): Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268: 1278–1283
von Moltke LL, Greenblatt DJ, Court MH, Duan SX, Harmatz JS, Shader RI . (1995): Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: Comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharm 15: 125–131
von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, Shader RI . (1998): Multiple human cytochromes contribute to biotransformation of dextromethorphan in vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol 50: 997–1004
von Moltke LL, Greenblatt DJ, Harmatz JS, Shader RI . (1993): Alprazolam metabolism in vitro: Studies of human, monkey, mouse, and rat liver microsomes. Pharmacology 47: 268–276
von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI . (1996a): Triazolam biotransformation by human liver microsomes in vitro. Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276: 370–379
von Moltke LL, Greenblatt DJ, Duan SX, Harmatz JS, Wright CE, Shader RI . (1996b): Inhibition of terfenadine metabolism in vitro by azole antifungals agents and by selective serotonin reuptake inhibitor antidepressants: Relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 16: 104–112
von Moltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI . (1996c): Midazolam hydroxylation by human liver microsomes in vitro: Inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol 36: 783–791
Acknowledgements
This work was supported by Grants MH-34223, MH-19924, and RR-00054 from the USPHS. Dr. Fogelman is the recipient of an American College of Neuropsychopharmacology Glaxo-Wellcome Fellowship in Clinical Neuropsychopharmacology. Dr. Schmider was the recipient of a Merck International Fellowship in Clinical Pharmacology. Dr. von Moltke is the recipient of a Scientist Development Award (K21-MH-01237) from the National Institutes of Mental Health.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fogelman, S., Schmider, J., Venkatakrishnan, K. et al. O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells: Effect of Metabolic Inhibitors and SSRI Antidepressants. Neuropsychopharmacol 20, 480–490 (1999). https://doi.org/10.1016/S0893-133X(98)00113-4
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(98)00113-4
Keywords
This article is cited by
-
Physiologically Based Pharmacokinetic Modeling to Unravel the Drug-gene Interactions of Venlafaxine: Based on Activity Score-dependent Metabolism by CYP2D6 and CYP2C19 Polymorphisms
Pharmaceutical Research (2024)
-
Pharmacokinetic correlates of venlafaxine: associated adverse reactions
European Archives of Psychiatry and Clinical Neuroscience (2019)
-
Functional and structural characterisation of common cytochrome P450 2D6 allelic variants—roles of Pro34 and Thr107 in catalysis and inhibition
Naunyn-Schmiedeberg's Archives of Pharmacology (2019)
-
Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database
European Journal of Clinical Pharmacology (2019)
-
WhichP450: a multi-class categorical model to predict the major metabolising CYP450 isoform for a compound
Journal of Computer-Aided Molecular Design (2018)
